Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly Kicks Off a Clinical Trial for a Second COVID-19 Antibody Treatment

By Prosper Junior Bakiny – Jun 8, 2020 at 12:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical powerhouse is developing JS016 in partnership with China-based Junshi Biosciences.

Eli Lilly (LLY -0.47%) has been doing its part in the fight against COVID-19. On June 1, the pharma giant began a clinical trial for a potential antibody treatment for the disease called LY-CoV555, which it is developing in collaboration with privately held biotech AbCellera. Now, Eli Lilly is initiating a phase 1 clinical trial for a second potential COVID-19 treatment, an antibody called JS016, this time in partnership with China-based Junshi Biosciences. Eli Lilly will conduct a study of JS016 in the U.S., while Junshi will conduct one in China.

As early-stage trials, these studies will test the safety, tolerability, immunogenicity (the ability to trigger an immune response in the body), and pharmacokinetics (the way the body processes the treatment) in healthy volunteers who haven't been diagnosed with the novel coronavirus. Contingent on positive results from these clinical trials, Eli Lilly will move on to evaluating JS016's efficacy. Note that Junshi Biosciences holds the rights to JS016 in China, while Eli Lilly owns the rights to it in the rest of the world.

Face mask with the word "COVID-19" written on it on a red background.

Image Source: Getty Images.

Big plans 

Although Eli Lilly has already advanced two potential COVID-19 antibody treatments to clinical trials, the pharma giant does not plan to stop there. The company says it hopes to develop a "portfolio of monotherapy and combination antibody regimens ... in order to understand which provide the best efficacy and tolerability in patients." The company has other antibody treatments in preclinical development, which means we can expect it to announce more clinical trials for potential COVID-19 treatments soon. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.